Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASTER
2024-515404-39-00Phase 3Authorised
- Sponsor
- Central Denmark Region
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Atorvastatin with Placebo (2 arms). Primary endpoint: Invasive disease-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
atorvastatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-515404-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515404-39-00.